다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

MESO

Mesoblast (MESO)

Mesoblast Limited

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:MESO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/19	09:08	GlobeNewswire Inc.	Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy	NASDAQ:MESO	Mesoblast Limited
2024/12/18	21:30	GlobeNewswire Inc.	Mesoblast to be Added to Nasdaq Biotechnology Index	NASDAQ:MESO	Mesoblast Limited
2024/12/14	06:04	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:MESO	Mesoblast Limited
2024/12/10	06:21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
2024/12/05	08:32	GlobeNewswire Inc.	FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
2024/12/03	08:20	GlobeNewswire Inc.	Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation	NASDAQ:MESO	Mesoblast Limited
2024/11/18	20:47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
2024/10/31	08:11	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024	NASDAQ:MESO	Mesoblast Limited
2024/10/10	04:42	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:MESO	Mesoblast Limited
2024/09/30	09:55	GlobeNewswire Inc.	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch	NASDAQ:MESO	Mesoblast Limited
2024/08/29	20:14	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
2024/08/29	08:27	GlobeNewswire Inc.	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024	NASDAQ:MESO	Mesoblast Limited
2024/08/28	08:25	GlobeNewswire Inc.	Mesoblast Financial Results and Corporate Update Webcast	NASDAQ:MESO	Mesoblast Limited
2024/07/31	10:13	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024	NASDAQ:MESO	Mesoblast Limited
2024/07/23	20:53	GlobeNewswire Inc.	FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	NASDAQ:MESO	Mesoblast Limited
2024/07/22	09:45	GlobeNewswire Inc.	Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain	NASDAQ:MESO	Mesoblast Limited
2024/07/09	09:37	GlobeNewswire Inc.	Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	NASDAQ:MESO	Mesoblast Limited
2024/07/01	14:55	GlobeNewswire Inc.	Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week	NASDAQ:MESO	Mesoblast Limited
2024/06/03	09:23	GlobeNewswire Inc.	Mesoblast Corporate Presentation at Investor Conference	NASDAQ:MESO	Mesoblast Limited
2024/04/30	10:05	GlobeNewswire Inc.	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	NASDAQ:MESO	Mesoblast Limited
2024/03/26	22:25	AllPennyStocks.com	FDA Commentary Sends Biotech Soaring During Premarket Hours	NASDAQ:MESO	Mesoblast Limited
2024/03/26	11:34	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	NASDAQ:MESO	Mesoblast Limited
2024/03/14	08:30	GlobeNewswire Inc.	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	NASDAQ:MESO	Mesoblast Limited
2024/03/11	08:54	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	NASDAQ:MESO	Mesoblast Limited
2024/02/29	07:57	GlobeNewswire Inc.	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	NASDAQ:MESO	Mesoblast Limited
2024/02/26	21:00	GlobeNewswire Inc.	Mesoblast Financial Results and Corporate Update Webcast	NASDAQ:MESO	Mesoblast Limited
2024/02/15	09:46	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
2024/02/01	11:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
2024/01/31	11:13	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	NASDAQ:MESO	Mesoblast Limited
2024/01/19	09:28	Dow Jones News	Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment	NASDAQ:MESO	Mesoblast Limited

검색 관련기사 보기:NASDAQ:MESO

1 2 3 4 5 6 7 8 9 10 다음 >>

Health Care Select Sector

Bank of America

JP Morgan Chase

US Dollar vs Sterling

Deutsche Telekom (QX)

US Dollar vs Yen

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관